Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid.

Bernauer, W; Schuler, S; Borradori, Luca (2018). Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid. Journal of ophthalmic inflammation and infection, 8(1), p. 12. Springer 10.1186/s12348-018-0153-8

Preview

Text Rituximab.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

BACKGROUND

B cell depleting therapy is widely used for lymphoproliferative diseases and immune-mediated disorders, including mucous membrane pemphigoid. The latter is an autoimmune blistering disease affecting predominantly the mucosae potentially associated with devastating complications.

METHODS

A 71-year-old patient with severe mucous membrane pemphigoid involving ocular, oral pharyngeal and laryngeal involvement is described. To control the disease, the patient was given rituximab therapy in combination with oral corticosteroids. He subsequently experienced an epithelial herpes simplex virus keratitis in one eye and 3 months later in his fellow eye. Topical treatment with ganciclovir resulted in prompt recovery.

RESULTS

For the first time, a correlation between rituximab and bilateral epithelial herpes simplex virus keratitis is described.

CONCLUSIONS

Although rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.

Interest & Impact

Downloads

208 since deposited on 30 Nov 2018
17 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item